Azeb Tadesse Argaw,Linnéa Asp,Jingya Zhang,Trinh Pham,John N. Mariani,Dipankar J. Dutta,Elisabeth G. Kramer,Napoleone Ferrara,Michael V. Sofroniew,Gareth R. John
出处
期刊:Neurology [Lippincott Williams & Wilkins] 日期:2014-04-08卷期号:82 (10_supplement)
标识
DOI:10.1212/wnl.82.10_supplement.p1.156
摘要
OBJECTIVE AND BACKGROUND: In inflammatory CNS conditions such as multiple sclerosis (MS), current options to treat clinical relapse are limited, and more selective agents are needed. Disruption of the blood-brain barrier (BBB) is an early feature of lesion formation that correlates with clinical exacerbation, and predisposes to edema, excitotoxicity, and entry of serum proteins and inflammatory cells. DESIGN/METHODS: Here, we identify astrocytic expression of the angiogenic factor VEGF-A as a key driver of BBB permeability in vivo. RESULTS: In GfapCre:Vegfafl/fl mice, BBB breakdown, lymphocyte infiltration and neuropathology were restricted in inflammatory and demyelinating lesions, and paralysis was reduced in experimental autoimmune encephalomyelitis (EAE), a model of MS. Knockdown studies in CNS endothelium revealed activation of the downstream effector, endothelial nitric oxide synthase (eNOS) as a principal mechanism underlying effects of VEGF-A on the BBB. Systemic administration of the selective eNOS inhibitor cavtratin abrogated VEGF-A-induced BBB disruption and pathology in vivo, and cavtratin therapy protected against neurologic deficit in mice with EAE. CONCLUSIONS: Collectively, these data identify blockade of VEGF-A signaling as a protective strategy to treat inflammatory CNS disease. Study Supported by: NINDS R01 NS062703, NMSS RG4127, The Guthy-Jackson Charitable Foundation, The Muzio Foundation.